CWBR vs. ONCO, RNAZ, AGRX, NBY, CYTO, CYCC, SXTP, ARAV, DRMA, and CNSP
Should you be buying CohBar stock or one of its competitors? The main competitors of CohBar include Onconetix (ONCO), TransCode Therapeutics (RNAZ), Agile Therapeutics (AGRX), NovaBay Pharmaceuticals (NBY), Altamira Therapeutics (CYTO), Cyclacel Pharmaceuticals (CYCC), 60 Degrees Pharmaceuticals (SXTP), Aravive (ARAV), Dermata Therapeutics (DRMA), and CNS Pharmaceuticals (CNSP). These companies are all part of the "pharmaceutical preparations" industry.
Onconetix (NASDAQ:ONCO) and CohBar (NASDAQ:CWBR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.
Onconetix's return on equity of 0.00% beat CohBar's return on equity.
In the previous week, Onconetix had 2 more articles in the media than CohBar. MarketBeat recorded 2 mentions for Onconetix and 0 mentions for CohBar. CohBar's average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.
CohBar received 18 more outperform votes than Onconetix when rated by MarketBeat users.
23.9% of Onconetix shares are owned by institutional investors. Comparatively, 2.5% of CohBar shares are owned by institutional investors. 19.5% of Onconetix shares are owned by insiders. Comparatively, 6.5% of CohBar shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
CohBar has lower revenue, but higher earnings than Onconetix. CohBar is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
Onconetix has a beta of 3.34, suggesting that its stock price is 234% more volatile than the S&P 500. Comparatively, CohBar has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.
Summary
Onconetix beats CohBar on 7 of the 11 factors compared between the two stocks.
Get CohBar News Delivered to You Automatically
Sign up to receive the latest news and ratings for CWBR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CWBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
